Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Discovery Platform
Sponsor : Novo Nordisk
Deal Size : Undisclosed
Deal Type : Collaboration
Gensaic, Novo Nordisk Partner to Unlock Next-Gen Precision Therapies
Details : The collaboration unites Novo's deep therapeutic knowledge and drug development experience with Gensaic’s novel protein design technology with the aim to treat cardiometabolic disease.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $354.0 million
March 03, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Discovery Platform
Sponsor : Novo Nordisk
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Discovery
Sponsor : Cystic Fibrosis Foundation
Deal Size : $3.5 million
Deal Type : Funding
Details : Gensaic will use the net proceeds to develop full CFTR gene delivery to lung tissue using its proprietary phage-derived particle (PDP) platform in CFTR-based gene Therapy.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 01, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Discovery
Sponsor : Cystic Fibrosis Foundation
Deal Size : $3.5 million
Deal Type : Funding